Green Thumb Industries vs. Curaleaf Holdings: Which Cannabis Stock Could Win Biggest From DEA Rescheduling?

DEA rescheduling cannabis from Schedule I to Schedule III could materially ease 280E tax pressure for U.S. cannabis operators, improving profitability and free cash flow. Green Thumb looks the stronger low-risk play with 2025 revenue of $1.2B, $348.4M normalized EBITDA, $295M operating cash flow, and Q1 2026 GAAP net income of $15.4M versus $324.2M revenue and $63.4M adjusted EBITDA for Curaleaf. The article argues Curaleaf has higher upside leverage if tax relief and broader reform significantly lift industry margins.

Analysis

The real implication of Schedule III is not just a one-time tax reset; it changes the entire cost of capital stack for the survivors. The winners will be the operators that already have enough scale to convert incremental pretax earnings into free cash flow rather than just plugging holes in the balance sheet. That favors the best-capitalized names, because once 280E pressure eases, lenders and equity markets will start underwriting them more like normal consumer staples/vice hybrids instead of distressed microcaps.

Green Thumb is the cleaner expression of that thesis because it has already proven it can self-fund without chronic dilution. In a market where many peers will use any tax relief to refinance, Green Thumb can redirect incremental cash toward buybacks, selective M&A, and state-market density, which should support multiple expansion more than headline EPS alone. The second-order effect is that stronger operators may actually gain share as weaker competitors lose the ability to subsidize growth through capital raises.

Curaleaf is the more convex trade because lower current margins mean a larger percentage lift if taxes step down materially, but that upside is conditional on reform being durable and capital markets staying open. The international business adds an important hedge against U.S. policy slippage, yet it also creates execution dispersion: Europe can offset U.S. delays, but it does not solve balance-sheet sensitivity if domestic pricing weakens or reform gets delayed. In other words, Curaleaf is a leveraged call option on reform; Green Thumb is a compounding asset with less upside torque but much better downside control.

The consensus risk is assuming that rescheduling immediately translates into rerating across the group. The market may initially overestimate how quickly savings flow through, since state taxes, banking frictions, and limited federal legality still constrain operations. The best near-term setup is likely a spread trade between quality and leverage rather than an outright sector bet, because the first beneficiaries of reform are operational discipline and liquidity, not just revenue growth.

Key Decisions for Investors

• Long GTBIF vs. CURLF on a 3-6 month horizon: favor the higher-quality balance sheet and buyback-supported compounding while capturing sector rerating. Risk/reward skews 2:1 if reform proceeds, with lower drawdown risk than an outright basket long.
• If seeking convexity, buy CURLF calls or small common position into any weakness over the next 1-2 months. This is a higher-beta trade on reform execution; size modestly because leverage can cut both ways if timing slips.
• Pair trade: long GTBIF / short a weaker, more levered U.S. MSO basket. The thesis is that tax relief will widen the gap between self-funders and capital-dependent peers over the next 6-12 months.
• Take profits on any sector-wide spike before full reform details are priced. The initial move may be faster than the fundamental realization cycle; expect the market to front-run cash flow improvement by 1-2 quarters.
• Use options rather than outright longs if entering pre-catalyst: call spreads on GTBIF for a defined-risk exposure to rerating, and smaller directional exposure on CURLF due to higher balance-sheet volatility.